KYXATA

Launch

carboplatin

Viatris (2)

NDAINTRAVENOUSSOLUTION

Approved

Aug 2025

Lifecycle

Launch

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.

Pharmacologic Class:

Platinum-based Drug

Indications (1)

for the initial treatment of advanced ovarian carcinoma

Clinical Trials (5)

NCT04832438Phase 2Withdrawn

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Started Dec 2030

NCT07229339Phase 2Not Yet Recruiting

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Started Jun 2027

NCT07472517Phase 3Not Yet Recruiting

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Started Apr 2026

670 enrolled

Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT07432594Phase 2Not Yet Recruiting

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Started Mar 2026

NCT07062354Phase 2Not Yet Recruiting

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Started Feb 2026

50 enrolled

Head &Amp; Neck CancerHead &Amp; Neck Squamous Cell Carcinoma